NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 312 filers reported holding NOVOCURE LTD in Q4 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $111,273 | -64.4% | 6,892 | -8.3% | 0.00% | -100.0% |
| Q2 2023 | $312,290 | -34.4% | 7,519 | -4.6% | 0.00% | 0.0% |
| Q1 2023 | $476,208 | -30.4% | 7,878 | -15.6% | 0.00% | 0.0% |
| Q4 2022 | $684,088 | -12.3% | 9,334 | -9.1% | 0.00% | -50.0% |
| Q3 2022 | $780,000 | -3.3% | 10,263 | -11.5% | 0.00% | 0.0% |
| Q2 2022 | $807,000 | -14.0% | 11,591 | -0.3% | 0.00% | 0.0% |
| Q1 2022 | $938,000 | +13.6% | 11,626 | +6.0% | 0.00% | 0.0% |
| Q4 2021 | $826,000 | -20.3% | 10,972 | +22.9% | 0.00% | 0.0% |
| Q3 2021 | $1,036,000 | -75.1% | 8,930 | -52.8% | 0.00% | -77.8% |
| Q2 2021 | $4,162,000 | +237.8% | 18,910 | +103.0% | 0.01% | +200.0% |
| Q1 2021 | $1,232,000 | -62.5% | 9,313 | -50.9% | 0.00% | -66.7% |
| Q4 2020 | $3,283,000 | +29.4% | 18,978 | -18.5% | 0.01% | +12.5% |
| Q3 2020 | $2,538,000 | +330.2% | 23,282 | +134.5% | 0.01% | +300.0% |
| Q2 2020 | $590,000 | -74.6% | 9,929 | -82.0% | 0.00% | -80.0% |
| Q1 2020 | $2,327,000 | – | 55,028 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |